Once-daily netarsudil was noninferior to twice-daily timolol for IOP-lowering efficacy in patients with open-angle glaucoma or ocular hypertension, according to the phase 3 ROCKET-4 study.
“In ROCKET-4, a large multicenter trial that was published in the American Journal of Ophthalmology this year, netarsudil once daily was noninferior to timolol used twice day. This effect persisted at various baseline IOPs for the duration of the study. There were no systemic side effects for netarsudil, unlike timolol, which led to the expected reduction in heart rate,” lead study author Albert
Uncategorized